◆ 会议时间：2020年4月3-7日 线上会议：2020年11月28日至12月1日
◆ 会议地点：奥地利 维也纳
◆ 下届会议：2021年第40届欧洲放射治疗与肿瘤学会年会(ESTRO2021)


◆ 会议简介：

2020年第39届欧洲放射治疗与肿瘤学会(ESTRO)年会-线上会议将2020年11月28日至12月1日举行，ESTRO年会是欧洲最大的放射肿瘤学会议与展览会，同时，2020年世界近距离放射治疗大会将于2020年7月31日至8月4日在同地举行，点此查看该会议。

欧洲放射治疗与肿瘤学学会(ESTRO)成立于1980年，是一个非营利性科学组织。ESTRO在欧洲内外拥有超过7600名成员，其中包括放射肿瘤学家、医学物理学家、放射生物学家和RTT（放射治疗师）以及肿瘤学界的其他相关专业人员。ESTRO致力于通过代表大会、特别会议、教育课程和出版物等，不断促进放射治疗学在多种肿瘤临床治疗中的应用，以改善对患者的护理。

ESTRO通过组织放射肿瘤学和癌症多学科治疗各方面的会议使其在国际上享有盛誉，其中既有数千名代表参与的大型会议，亦有高度专业化的团体会议。同时，ESTRO也多次与其他国际知名学术组织合作，使会议成为一个能够充分交流知识和经验的平台。 —领域国际医学会议网翻译整理，未经本站允许，禁止复制、转载本站任何内容。

重要日期：
Abstract submission: 23 October 2019
Early registration: 14 January 2020
Late abstract submission: 15 January 2020
Late registration: 12 November 2020

It is my privilege and great pleasure to invite you to ESTRO 39 that will take place 3-7 April 2020 in Vienna, Austria. 

We are pleased that this year the World Congress of Brachytherapy will take place adjacent to ESTRO 39 from 2-4 April 2019 in the same venue as ESTRO 39.

ESTRO is a multi-professional society focusing on radiation oncology as a core component of high- quality, multidisciplinary cancer treatment, in partnership with other oncology societies.

Radiotherapy is a team effort, delivered by an interdisciplinary team consisting of radiation oncologists, clinical oncologists, medical physicists, radiobiologists, radiation therapists (RTTs) and nurses. The Society wishes to engage them all in their congress, together and in discussion with other oncology specialists.

In line with the ESTRO vision 2030 ‘Radiation Oncology. Optimal Health for all, together’, ESTRO 39 will convey the theme ‘Translating research and partnership into optimal health’.

Advances in technologies and methodologies of radiation oncology continue to evolve very rapidly. However, these innovations will only truly provide impact when the new findings can be translated into clinical applications that will result in optimal benefit for each individual patient in daily practice. Radiation oncology professionals should not try to achieve such optimal outcome by themselves but in dialogue and partnership with all relevant stakeholders: other oncology specialists at national, European and international level; patient representatives and advocates; and, industry partners. ESTRO 39 aims at stimulating all stakeholders to enhance and shape radiotherapy for optimal health for each cancer patient.

The comprehensive scientific programme at ESTRO 39 offers state-of-the-art teaching lectures, symposia, debates on hot topics, as well as a range of educational activities such as pre-meeting courses, contouring workshops, and multidisciplinary tumour boards.

We put extra effort in optimising the programme format of ESTRO 39 by giving more room and visibility to contributions from abstract submissions. Sessions with highlights of proffered papers will take place in a plenary setting, offering maximum visibility to your work. Furthermore, we will aim to give more visibility to posters by increasing the number of posters that will be discussed offering you a platform to showcase your achievements. You are therefore strongly encouraged to submit an abstract by 23 October 2019 and become part of this prestigious event. Late breaking abstract submission will also be possible
as of early January 2020 and within the deadline of 15 January 2020.

The interdisciplinary component of the scientific programme, getting more space compared to the past editions, will include sessions on the following topics:
• How can AI improve contouring?
• Spatially fractionated radiation therapy (SFRT) - GRID therapy
• Cancer metabolism: implication for imaging, radiation response prediction and tumor radiosensitisation
• Cardiac radio-ablation
• FLASH: Radiotherapy with ultra-high dose rates
• Ultra-hypofractionation for localised prostate cancer
• Management of complex skin targets: which radiation technique
• MR-guided Radiotherapy: state of the art and future perspectives
• Preventing radiation-induced toxicity for the H&N region
• Dose accumulation and re-irradiation for breast and thorax
• How PROMS will change radiotherapy practice
• Targeting microenvironment in radiotherapy: where are we now?
• Redefining oligometastatic disease: incorporating advanced imaging into clinical trials
• Combined radiotherapy and immunotherapy in NSCLC

Once again young members are working on preparing a dedicated Young Scientists Track encompassing relevant lectures and other activities. This will provide a unique opportunity to network and the possibility of becoming involved in, or even starting international and domestic projects.

ESTRO 39 houses Europe’s largest industrial exhibition in radiation oncology, offering you a unique opportunity to interact with industry leaders and to find here the latest developments in technology, techniques and oncology products.

We look forward to welcoming you in Vienna.

With warm regards, 

Umberto Ricardi
ESTRO 39 Chair

ESTRO 2020-注册费:

Registration fees for ESTRO 2020

Fees including 21% VAT  

Reduced fees apply to ESTRO members

Pre-meeting courses
To register for pre-meeting courses, please register seperataly for each pre-meeting here.

Cancel my registration – You can cancel your registration and get a full refund of the registration fee minus handling charges of 15%. This option is available until 2 months before ESTRO 2020, i.e. until 28 September 2020. Between 28 September and 12 November 2020, the refund will amount to 50% of the registration fee. No refund will be possible if the cancellation is postmarked after 12 November 2020.

* To register as a student you should be an ESTRO member and send your valid student card to events@estro.org before completing the registration. Institute letters are not accepted.
** ESTRO Members with speciality RTT may register at the In-training fee.
*** Participants from emerging countries may register at a preferential rate before 12 November 2020. After this date the desk fee will apply. Emerging country rate applies to individuals from low-income and lower-middle-income economies according to the World Bank listing available.

◆ 参会对象：
政府代表、医院管理者、科室主任、副主任、医生及从相关领域研究的专家、科研人员、医药企业等。